

REFERENCES

- (1) World Health Organization Expert Committee on Diabetes Mellitus. Second WHO Technical Report, Series 310. Geneva: World Health Organization, 1965.
- (2) National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28(1979): 1039-57.
- (3) World Health Organization Expert Committee on Diabetes Mellitus. Second WHO Technical Report, Series 646. Geneva: World Health Organization, 1980.
- (4) World Health Organization Expert Committee on Diabetes Mellitus. Second WHO Technical Report, Series 727. Geneva: World Health Organization, 1985.
- (5) World Health Organization Consultation. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications, Part 1: Diagnosis and Classification of Diabetes Mellitus. Report of a WHO Consultation. Geneva: World Health Organization, 1999.
- (6) Pickup, J. C.; and Williams, G. Text book of Diabetes: Selected Chapters. pp2-45. Italy: Blackwell Publishing, 2005.
- (7) Su-Yen, G.; and Cooper, M. E. The role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 93(4) (April 2008): 1143-52
- (8) Jakus, V.; and Rietbrock, N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol. Res.53(2004):131-142
- (9) Globocnik, P. M.; Steblovnik, K.; Peterlin, B.; and Petrovic, D. The - 429 T/C and - 374 T/A gene polymorphisms of the receptor of advanced glycation end products gene are not risk factors for diabetic retinopathy in Caucasians with type 2 diabetes. Klin. Monatsbl. Augenheilkd. 220(12) (December 2003):873-6
- (10) dos Santos, K.G.; Canani, L. H.; Gross, J. L.; Tschiedel, B. T.; Souto, K. E. P.; and Roisenberg, I. The -374A allele of the receptor for advanced glycation end products gene is associated with a decreased risk of ischemic heart disease in African-Brazilians with type 2 diabetes. Molecular Genetics and Metabolism. 85(2005): 149-156

- (11) UGDP. A study of the effects of hypoglycemic agent on vascular complication in patients with adult onset diabetes, 2: mortality results. Diabetes. 19 (1970): 111-15
- (12) HU, S.; Wang, S.; and Fanelli, B. Pancreatic beta-cell K (ATP) channel activity and membrane-binding studies with nateglinide: a comparison with sulphonylureas and repaglinide. J. Pharmacol. Exp. Ther. 293(2000): 444-52
- (13) Bailey, C. J. Potential new treatment for type 2 diabetes. Trends Pharm Sci. 21(2000): 259-65
- (14) Yeh, G. Y.; Kaptchuk, T. J.; Eisenberg, D. M.; and Phillips, R.S. Systematic review of herbs and dietary supplements for glycemic control in diabetes, Diabetes Care. 26(4) (April 2003)(4): 1277-97
- (15) Kimura, I. Medical benefits of using natural compounds and their derivatives having multiple pharmacological actions. The Pharmaceutical Society of Japan. 126 (3)(2006): 133-43
- (16) Bone, K. Gymnema: a key herb in the management of diabetes-Phytotherapy review & commentary. Townsend letter for Doctors and Patients. 2002 Dec.
- (17) Shanmugasundaram, K.R.; and Panneerselvam, C. The insulinotropic activity of gymnema sylvestre R.Br. an Indian herb used in controlling diabetes mellitus. Pharmaco. Res. Commu. 13 (1981): 475-86
- (18) Shanmugasundaram, K. R.; Panneerselvam, C.; Samudram, P.; and Shanmugasundaram, E. R. B. Enzyme changes and glucose utilisation in diabetic rabbits: the effects of *Gymnema sylvestre*, R.Br. J. Ethnopharmacol. 7(1983): 205-34
- (19) Shanmugasundaram, E. R. B.; Rajeswari, G.; Baskaran, K.; Rajeshkumar, B. R.; Shanmugasundaram, K. R.; and Ahmath, B. Use of *Gymnema sylvestre* leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus, J. Ethnopharmacol. 30(1990):281-94
- (20) Baskaran, K.; Ahamath, B. K.; Shanmugasundaram, K.R.; and Shanmugasundaram, E. R. B.; Antidiabetic effect of a leaf extract from *Gymnema sylvestre* in non-insulin-dependent diabetes mellitus patients. J. Ethnopharmacol. 30(1990): 295-305

- (21) Murakami, N.; Murakami, T.; Kadoya, M.; Matsuda, H.; Yamahara, J.; and Yoshikawa, M. New hypoglycemic constituents in "gymnemic acid" from *Gymnema sylvestre*. Chem. Pharm. Bull. (Tokyo). 44(2)(February 1996): 469-71
- (22) Yoshikawa, M.; Murakami, T.; Kadoya, M.; Li, Y.; Murakami, N.; Yamahara, J.; and Matsuda, H. Medicinal foodstuffs. IX: The inhibitors of glucose absorption from the leaves of *Gymnema sylvestre* R. BR. (Asclepiadaceae): structures of gymnemosides a and b. Chem. Pharm. Bull.(Tokyo). 45(10)(October 1997): 1671-6
- (23) Persaud, S.J.; Al-Majed, H.; Raman, A.; and Jones, P.M. *Gymnema sylvestre* stimulates insulin release in vitro by increased membrane permeability. J.Endocrinology. 163(1999):207-12
- (24) Sugihara, Y. Antihyperglycemic effects of gymnemic acid IV, a compound derived from *Gymnema sylvestre* leaves in streptozotocin-diabetic mice. J. Asian Nat. Prod. Res. 2(4)(2000):321-7
- (25) Gent, J.F.; Hettinger, T.P.; Frank, M.E.; and Marks, L.E. Taste confusions following gymnemic acid rinse. Chem. Senses. 24(4)(August 1999): 393-403
- (26) Alberti, K.G.M.M.; and Zimmet, P.Z. for the WHO Consultation. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications, Part 1: Diagnosis and Classification of Diabetes Mellitus. Previsional Report of a WHO Consultation. Diabetes Med. 15(1998): 539-53
- (27) Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 24 (2001): S5-29
- (28) DeFronzo, R.A.; Goodman, A.M. Efficiency of Metformin in patients with non-insulin-dependent- diabetes mellitus. The multicenter Metformin Study Group. N. Eng. J. Med. 128(1998): 167-75
- (29) Hammes, H.P.; Alt, A.; Niwa, T.; Clausen, J.T.; Bretzel, R.G.; Brownlee, M.; and Schleicher, E.D. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia. 42(1999):728-36
- (30) Bucala, R.; Vlassara, H. Advanced glycosylation end products in diabetic renal and vascular disease. Am. J. Kidney Dis. 26(1995) :875-88

- (31) Makita, Z.; Bucala, R.; Rayfield, E.J.; Friedman, E.A.; Kaufman, A.M.; Korbet, S.M.; Barth, R.H.; Winston, J.A.; Fuh, H.; and Manogue, K.R. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet. 343(1994):1519–22
- (32) Nathan, D.M.; Lachin, J.; Cleary, P.; Orchard, T.; Brillon, D.J.; Backlund, J.Y.; O'Leary, D.H.; and Genuth, S, Diabetes Control and Complications Trial, Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N. Engl.J. Med. 348(2003):2294–303
- (33) Monnier, V.M.; Bautista, O.; Kenny, D.; Sell, D.R.; Fogarty, J.; Dahms, W.; Cleary, P.A., Lachin, J.; and Genuth, S. 1999 Skin collagen glycation, glycooxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes. 48(1999):870–80
- (34) Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 290(2003):2159–2167
- (35) Miyata, T.; Ueda, Y.; Horie, K.; Nangaku, M.; Tanaka, S.; van Ypersele de Strihou, C., and Kurokawa, K. Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int. 53(1998):416–422
- (36) Soulis-Liparota, T.; Cooper, M.E.; Dunlop, M.; and Jerums, G. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia. 38(1995):387–39
- (37) Oldfield, M.D.; Bach, L.A.; Forbes, J.M.; Nikolic-Paterson, D.; McRobert, A.; Thallas, V.; Atkins, R.C.; Osicka, T.; Jerums, G.; and Cooper, M.E. Advanced glycation

- end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J. Clin. Invest. 108(2001):1853–63
- (38) Vlassara, H. Striker, L.J.; Teichberg, S.; Fuh, H.; Li, Y.M.; and Steffes, M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl. Acad. Sci. USA. 91(1994):11704–8
- (39) Tsuchida, K.; Makita, Z.; Yamagishi, S.; Atsumi, T.; Miyoshi, H.; Obara, S.; Ishida, M.; Ishikawa, S.; Yasumura, K.; and Koike, T. Suppression of transforming growth factor β and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia. 42(1999):579–88
- (40) Forbes, J.M.; Soulis, T.; Thallas, V.; Panagiotopoulos, S.; Long, D.M.; Vasan, S.; Wagle, D.; Jerums, G.; and Cooper, M.E. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia. 44 (2001):108–14
- (41) Forbes, J.M.; Thallas, V.; Thomas, M.C.; Founds, H.W.; Burns, W.C.; Jerums, G.; and Cooper, M.E. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. 17(2003):1762–4
- (42) Flyvbjerg, A.; Denner, L.; Schrijvers, B.F.; Tilton, R.G.; Mogensen, T.H.; Paludan, S.R.; and Rasch, R.; Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes. 53(2004):166–72
- (43) Murata, T.; Nagai, R.; Ishibashi, T.; Inomuta, H.; Ikeda, K.; and Horiuchi, S. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia. 40(1997):764–9
- (44) Stitt, A.W. Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br. J. Ophthalmol. 85(2001):746–53
- (45) Stitt, A.W.; Li, Y.M.; Gardiner, T.A.; Bucala, R.; Archer, D.B.; and Vlassara, H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am. J. Pathol. 150(1997):523–53

- (46) Stitt, A.W.; Bhaduri, T.; McMullen, C.B.; Gardiner, A.; and Archer, D.B. Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol. Cell. Biol. Res. Commun. 3(2000):380–8
- (47) Chakravarthy, U.; Hayes, R.G.; Stitt, A.W.; McAuley, E.; and Archer, D.B. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes. 47(1998):945–52
- (48) Lu, M.; Kuroki, M.; Amano, S.; Tolentino, M.; Keough, K.; Kim, I.; Bucala, R.; and Adamis, A.P. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J. Clin. Invest. 101(1998):1219–24
- (49) Chen, A.S.; Taguchi, T.; Sugiura, M.; Wakasugi, Y.; Kamei, A.; Wang, M.W.; and Miwa, I. Pyridoxal-aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats. Horm. Metab. Res. 36(2004):183–7
- (50) Vlassara, H.; Brownlee, M.; and Cerami, A. Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc. Natl. Acad. Sci. USA. 78(1981):5190–2
- (51) Okamoto, K.; Martin, D.P.; Schmelzer, J.D.; Mitsui, Y.; and Low, P.A. 2001 Pro- and anti-inflammatory cytokine gene expression in rat sciatic nerve chronic constriction injury model of neuropathic pain. Exp. Neurol. 169(2001):386–91
- (52) Bierhaus, A., Haslbeck, K.M., Humpert, P.M., Liliensiek, B., Dehmer, T., Morcos, M, Sayed AA, Andrassy M, Schiekofler S, Schneider JG, Schulz JB, Heuss D, Neundorfer B, Dierl S, Huber J, Tritschler H, Schmidt AM, Schwaninger M, Haering HU, Schleicher E, Kasper M, Stern DM, Arnold B, and Nawroth PP. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest. 114(2004):1741–51
- (53) Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, and Hanssen KF. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care. 22(1999):1543–8
- (54) Friedman, E.A. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Diabetes Care 22(1999):B65–71

- (55) Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest. 99(1997):457–68
- (56) Stitt AW, He C, Friedman S, Scher L, Rossi P, Ong L, Founds H, Li YM, Bucala R, Vlassara H. Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Mol. Med. 3(1997):617–27
- (57) Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA. 91(1994):9441–5
- (58) Sobenin IA, Tertov VV, Koschinsky T, Bunting CE, Slavina ES, Dedov II, Orekhov AN. 1993 Modified low density lipoprotein from diabetic patients causes cholesterol accumulation in human intimal aortic cells. Atherosclerosis. 100(1993):41–54
- (59) Kunt T, Forst T, Wilhelm A, Tritschler H, Pfuetzner A, Harzer O, Engelbach M, Zschaebitz A, Stofft E, Beyer R. alpha-lipoic acid reduces expression of vascular cell adhesion molecule-1 and endothelial adhesion of human monocytes after stimulation with advanced glycation end products. Clin. Sci. Lond. 96(1999) :75–82
- (60) Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, Cooper ME, Allen TJ. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes (2004)**53**:1813–1823
- (61) Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, Schmidt AM. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 106(2002):2827–35
- (62) Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care. 26(2003):2433–41
- (63) Berg TJ, Snorgaard O, Faber J, Torjesen PA, Hildebrandt P, Mehlsen J, Hanssen KF. Serum levels of advanced glycation end products are associated with left

- ventricular diastolic function in patients with type 1 diabetes. Diabetes Care. 22(1999):1186–90
- (64) Lapolla A, Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R, Baccarin L, Laverda B, Fedele D. Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care. 30(2007):670–6
- (65) Shimizu K, Ozeki M, Tanaka K, Itoh K, Nakjyo S, Urakawa N, and Atsuchi M, suppression of glucose absorption by extracts from the leaves of *Gymnema inodorum*. J Vet Med Sci. (1997); 59(9): 753-7
- (66) Shimizu K, Ozeki M, Iino A, Nakajyo S, Urakawa N, Atsuchi M, structure-activity relationship of triterpenoid derivatives extracted from *gymnema inodorum* leaves on glucose absorption, Jpn J Pharmacol. (Jan 2001); 86(2): 223-9
- (67) Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 414(2001):813–20
- (68) Thornalley JP. Advanced glycation and the development of diabetic complications: unifying the involvement of glucose, methylglyoxal and oxidative stress. Endocrinol Metab. 3(1996):149–66
- (69) Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R, Cerami A. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA (1997)94:13915–13920
- (70) Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H 1997 Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA. 94(1997) :6474–9
- (71) Nicholl ID, Stitt AW, Moore JE, Ritchie AJ, Archer DB, Bucala R 1998 Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers. Mol Med. 4(1998):594–601
- (72) Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, Peppia M, Rayfield EJ. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA. 99(2002):15596–601

- (73) Zheng F, He C, Cai W, Hattori M, Steffes M, Vlassara H. Prevention of diabetic nephropathy in mice by a diet low in glycooxidation products. Diabetes Metab Res Rev. 18(2002):224–37
- (74) Giardino I, Edelstein D, Brownlee M 1994 Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest. 94(1994):110–7
- (75) Brownlee M 1995 Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 46(1995):223–234
- (76) Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med. 28(1996):419–426
- (77) Haitoglou CS, Tsilibary EC, Brownlee M, Charonis AS. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J Biol Chem. 267(1992):12404–7
- (78) Ziemann SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 25(2005):932–43
- (79) Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M. PDGF and TGF- β mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int (1995)**48**:111–7
- (80) Forbes JM, Cooper ME, Oldfield MD, Thomas MC. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol. 14(2003):S254–8
- (81) Twigg SM, Cao Z, McLennan SV, Burns WC, Brammar G, Forbes JM, Cooper ME. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology . 143(2002):4907–15
- (82) Hudson BI, Hofmann MA, Bucciarelli L, Wendt T, Moser B, Lu Y, Qu W, Stern DM, Agati VD, Yan SD, Yan SF, Grant PJ, Schmidt AM . Glycation and diabetes: the RAGE connection. Current Science. 83(2005):1515-21
- (83) Hudson BI and Schmidt AM. RAGE: A novel target for drug intervention in diabetic vascular disease. Pharm Res . 21(2004):1079-86
- (84) Hudson BI, Stickland MH, Futers TS, and Grant PJ. Effects of novel polymorphism in RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes .50(2001):1505-11

- (85) Hudson BI, Stickland MH, Futers TS, and Grant PJ. Study of the -492T/C and -374T/A receptor for advanced glycation endproducts promoter polymorphisms in diabetic and non diabetic subjects with macrovascular disease. Diabetes Care. 24(2001):2004
- (86) XU J, Xu B, Yang M, and Liu S. -429T/C and -374T/A Polymorphism of RAGE gene promoter are not associated with diabetic retinopathy in Chinese patients with Type 2 Diabetes. Diabetes care. 29(9)(2003) : 2696-7
- (87) Petrovic MG, Stteblovnik K, Peterlin D, and Petrovic D. The -429T/C and -374T/A gene polymorphisms of the receptor of advanced glycation end products gene are not risk factors for diabetic retinopathy in Caucasians with type 2 diabetes. Klin Monatsbl. 220(2003):2696-7
- (88) Pettersson-Fernholm K, Forsblom C, Hudson BI, Perola M, and Grant PJ. The Functional -374 T/A RAGE Gene Polymorphism Is Associated With Proteinuria and Cardiovascular Disease in Type 1 Diabetic Patients. Diabetes. 52(2003) :891-894
- (89) Cicero AF, Derosa G, and Gaddi A, What do herbalists suggest to diabetic patients in order to improve glycemc control? Evaluation of scientific evidence and potential risks. Acta Diabetol. (2004) Sep;41(3):91-8.
- (90) Khare AK, Tondon RN and Tewari JP, Hypoglycaemic activity of an indigenous drug (Gymnema sylvestre, 'Gurma') in normal and diabetic persons. Indian J Physiol and Pharmacol . 27(1983): 257-8.
- (91) Shapiro K, and Gong WC, Natural Products Used for Diabetes. J Am Pharm Assoc (Wash). 42 (March-April 2002): 217-26.
- (92) Srivastava Y, Bhatt HV, Prem AS, Nigam SK, and Verma Y, hypoglycemic and life-prolonging properties of Gymnema sylvestre leaf extract in diabetic rats. Israel J Med Sci. 21(1985): 540-2
- (93) Sugihara Y, Nojima H, Matsuda H, Murakami T, Yoshikawa M, and Kimura I, antihyperglycemic effects of Gymnema sylvestre leaves in streptozotocin-diabetic mice. J Asian Nat Prod Res. 2(2000): 321-7
- (94) Kanetkar P/ Singghal R and Kamat M. Gymnema sylvestre: A memoir. J Clin Biochem Nutr. 41(2007):77-81

- (95) Falcone C, Campo I, Emanuele E, Buzzi MP, Sbarsi I, and Cuccia M. Relationship between the -374T/A RAGE gene polymorphism and angiographic coronary artery disease. Int J Mol Med. 14(2004):1061-4
- (96) Yonekura H, Yamamoto Y, Sakurai S, Watanabe T, Yamamoto H. Roles of the Receptor for advanced glycation endproducts in Diabetes-Induced Vascular injury. Journal of Pharmacological Sciences. 97(2005):305-11
- (97) Sakurai S, Yonekura H, Yamamoto Y, Watanabe T, Tanaka N, Li H, Rahman AK, Myint KM, Kim CH, Yamamoto H. The AGE-RAGE system and diabetic nephropathy. J Am Soc Nephrol. 14(3)(2003):259–63.
- (98) Naka Y, Bucciarelli LG, Wendt T, Lee LK, Rong LL, Ramasamy R, Yan SF, and Schmidt AM. RAGE axis: animal models and novel insights into the vascular complications of diabetes. Arterioscler Thromb Vasc Biol. 24(2004):1342–49
- (99) Yan S, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding protein. J Biol Chem. 296(1994):9889-97
- (100) Neumann A, Schinzel R, Palm D, Riederer P, Munch G. High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappaB activation and cytokine expression. FEBS Lett. (1999) ;453(3):283-7.
- (101) Tian J, Ishibashi K, Ishibashi K, Reiser K, Grebe R, Biswal S, et al. Advanced glycation endproduct-induced aging of the retinal pigment epithelium and choroid: a comprehensive transcriptional response. Proc Natl Acad Sci U S A. 102(33)(2005):11846-51
- (102) Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Ramasamy R, Arnold B, Nawroth PP, Yan SF, D'Agati V, Schmidt AM. Glucose, Glycation, and RAGE: Implications for Amplification of Cellular Dysfunction in Diabetic Nephropathy. J Am Soc Nephrol 14(2005):1383-95
- (103) Loeser RF, Yammani RR, Yan SD et al. Articular chondrocytes express the receptor for advanced glycation end products: Potential role in osteoarthritis. Arthritis & Rheumatism. 52(2005):2376-85
- (104) Rojas A, Morales MA. Advanced glycation and endothelial functions: A link towards vascular complications in diabetes. Life Sciences. 76(2004):715-30

- (105) Globocnik PM, Stevlonik K, Peterlin B, and Petrovic D. The -429T/C and -374T/A gene polymorphisms of the receptor of the advanced glycation end products gene are not risk factors for diabetic retinopathy in Caucasians with type 2 diabetes. Klin Monatsbl Augenheilkb. 220(2003):873-6
- (106) Natalucci S, Di Nardo F, Staffolani P, De Marzi C, Morosini P, and Burattini R. Glucose absorption and insulin sensitivity from oral glucose tolerance test. Proceedings of 25th Annual International Conference of the IEEE EMBS Cancun Mexico 2003: 2758-60
- (107) Gholamhoseinian A, Fallah H, Sharifi-far F, and Mirtajaddini M. The inhibitory effect of some Iranian Plants on the alpha glucosidase. Iran Jour Bas Med Sci 11(2008):1-9
- (108) Tunsaringkarn T, Rungsiyothin A, and Ruangrunsi N. α -glucosidase inhibitory activity of Thai minosaceous plant extracts. J health Res. 22(2008):29-33
- (109) Sugihara Y, Nojima H, Matsuda H, Murakami T, Yoshikawa M, Kimura I. Antihyperglycemic effects of gymnemic acid IV, a compound derived from *Gymnema sylvestre* leaves in streptozotocin-diabetic mice. J Asian Nat Prod Res. 2(2000):321-7
- (110) Hediger M, Rhoads D. Molecular physiology of sodium-glucose cotransporters. Physiol. Rev. 74(1994): 993–1026
- (111) Department of Biochemistry and Molecular Biophysics The University of Arizona. Membrane Transport[Online]. Available from: <http://www.biochem.arizona.edu/classes/bioc462/462a/lectures.html>[2009, May 15]
- (112) Sarker RI, Ogawa W, Shimamoto T, Shimamoto T, and Tsuchiya T. Primary structure and properties of Na⁺/Glucose symporter (SglS) of *Vibrio parahaemolyticus*. Jour Bact. 179(1997):1805-8
- (113) Jorgensen PL. Mechanism of the Na⁺,K⁺ pump protein structure and conformations of pure (Na⁺+K⁺)-ATPase. Biochimica et Biophysica Acta. 694(1982):27-68
- (114) Muangman T, Chongviriyaphan N, Molares NP, Pisalpong C, Klungsunya P, Suthutvoravur U, and Sungpuag P. Antioxidant activity and protective effects of *Gymnema inodorum* dence on red blood cell hemolysis and DNA damage in

- TK6 human lymphoblastoid cells[Online]. Available from: www.tistr.or.th/thesis/P15/abstract_2548/4_Thanyaluk_2548.pdf. [2009, May 1]
- (115) Kaneto H, Kajimoto Y, Miyagawa J, Matsuoka T, Fujitani Y, Umayahara Y, Hanafusa T, Matsuzawa Y, Yamasaki Y, and Hori M. Beneficial effects of antioxidants in diabetes: possible protection of pancreatic β -cells against glucose toxicity. *Diabetes*. 48(1999):2398-406
- (116) Baggio LL, Drucker DJ. Biology of incretin: GLP-1 and GIP. *Gastroenterology* 132(2007): 2131-57.
- (117) Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. *J Clin Endocrinol Metab*. 63(1986): 492-498.
- (118) Gerich JE. Metabolic abnormalities in impaired glucose tolerance. *Metabolism*. 46(1997): 40-43.
- (119) Vilsboll T, Krarup T, Deacon CF, et al. Reduced post prandial concentrations of intact biologically active glucagon-like peptide-1 in type 2 diabetic patients. *Diabetes*. 50(2001): 609-613.
- (120) Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. *Am J Physiol Endocrinol Metab*. 287(2004): E199-E206.
- (121) Vilsboll T, Krarup T, MacIsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and post prandial glucose levels and contribute nearly equally to the incretin effects of a meal in healthy subjects. *Regul Pept* 114(2003): 5-121.
- (122) Quddusi S, Vahl TP, Hanson K, et al. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first and second phase insulin secretion in diabetic and nondiabetic humans. *Diabetes Care* .26(2003): 791-798.
- (123) *Restriction mapper*[Online]. Available from: <http://www.restrictionmapper.org> [2009, May 1]
- (124) Clarimon, J.; Andres, A.M.; Bertranpetit, J.; and Comas, D. Comparative analysis of Alu insertion sequences in the APP 5' flanking region in humans and other primates. *J Mol Evol* .58(2004): 722-31



BIOGRAPHY

Miss Anchalee Chiabchalard was born on September 3rd, 1967 in Bangkok, Thailand. She graduated with Bachelor degree of Sciences in Medical Technology from Faculty of Medicine, Chulalongkorn University in 1989 and Master degree of Sciences in Biochemistry from Faculty of Sciences, Chulalongkorn University in 1994. She also graduated with Bachelor Degree of sciences in Biology (Cum Laude) from Oregon State University, USA in 1999. She has worked as an instructor in Department of Clinical Chemistry, faculty of Allied Health Sciences, Chulalongkorn University since 2001. She has studied for Docterate degree in Biomedical Sciences Program at Graduated School, Chulalongkorn University since 2003.